Lymphoma treatment often follows standardized approaches, even though these diseases vary widely in their molecular characteristics. Modern liquid biopsy methods—blood tests capable of detecting even the smallest tumor-derived molecules such as circulating tumor DNA (ctDNA)—now provide a much more precise view of disease biology and its dynamics over time. In this project, ultrasensitive ctDNA analyses are used to identify molecular changes through a simple blood draw, establish individualized risk profiles, and detect relapses early, before clinical symptoms appear. At the same time, the underlying biological mechanisms of these changes will be investigated, with the aim of translating these insights into practical diagnostic tools that enable personalized lymphoma therapy.